Screener
Abbott ABT Established Pharmaceuticals — Operating Earnings
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Abbott in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Abbott’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:02 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050134
| (in millions) | Net Sales to External Customers / Three Months Ended June 30, 2026 | Net Sales to External Customers / Three Months Ended June 30, 2025 | Cost of Products Sold / Three Months Ended June 30, 2026 | Cost of Products Sold / Three Months Ended June 30, 2025 | Research and Development / Three Months Ended June 30, 2026 | Research and Development / Three Months Ended June 30, 2025 | Selling, General, and Administrative / Three Months Ended June 30, 2026 | Selling, General, and Administrative / Three Months Ended June 30, 2025 | Operating Earnings / Three Months Ended June 30, 2026 | Operating Earnings / Three Months Ended June 30, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Established Pharmaceuticals | $1,499 | $1,383 | $(650) | $(631) | $(48) | $(43) | $(419) | $(363) | $382 | $346 |
| Nutritional Products | 2,144 | 2,212 | (1,148) | (1,155) | (54) | (54) | (574) | (585) | 368 | 418 |
| Diagnostic Products | 3,092 | 2,173 | (1,532) | (1,224) | (268) | (154) | (793) | (423) | 499 | 372 |
| Medical Devices | 5,853 | 5,369 | (1,925) | (1,758) | (470) | (430) | (1,489) | (1,385) | 1,969 | 1,796 |
| Total | $12,588 | $11,137 | $(5,255) | $(4,768) | $(840) | $(681) | $(3,275) | $(2,756) | $3,218 | $2,932 |
| Other | 5 | 5 | ||||||||
| Net sales | $12,593 | $11,142 | ||||||||
| Corporate functions and plan benefit costs | (45) | (65) |
Item 1. Financial Statements and Supplementary Data
FAQ
- What is Abbott's established pharmaceuticals — operating earnings?
- Abbott (ABT) reported established pharmaceuticals — operating earnings of $382M in Q2 2026.
- How has Abbott's established pharmaceuticals — operating earnings changed year-over-year?
- Abbott's established pharmaceuticals — operating earnings increased by 10.4% year-over-year, from $346M to $382M.
- What is the long-term trend for Abbott's established pharmaceuticals — operating earnings?
- Over 4 years (2021 to 2025), Abbott's established pharmaceuticals — operating earnings has grown at a 9.8% compound annual growth rate (CAGR), from $889M to $1.29B.
- What does established pharmaceuticals — operating earnings mean?
- This metric represents the profit generated by the established pharmaceuticals segment after deducting all operating expenses, including COGS, R&D, and SG&A. It is the primary measure of the segment's operational profitability and performance. Investors use this to assess the core health of the business unit independent of corporate-level financing or tax effects.
Ask your AI about Abbott's established pharmaceuticals — operating earnings.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude